8-K ·Filed May 26, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor market reaction to the Phase 3 data presentation. If data is positive, LPCN 1154 could become a significant asset; if negative, the stock may decline. Further details are in the exhibits.
Final — all horizons settled through T+60d
LPCN ▼ -8.33% at T+60d
NEUTRAL call -8.33% · α vs SPY -10.21% · entry $2.28 → $2.09
T+1d
-0.88%
call -0.88% · α -1.43%
$2.26
settled 5mo ago
T+5d
-3.95%
call -3.95% · α -4.42%
$2.19
settled 5mo ago
T+20d
+4.39%
call +4.39% · α +6.29%
$2.38
settled 4mo ago
T+60d
-8.33%
call -8.33% · α -10.21%
$2.09
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Lipocine announced the presentation of Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression at the ASCP Annual Meeting on May 26, 2026. The filing includes the presentation and poster as exhibits, but no specific efficacy or safety results are discussed in the 8-K.
Key Facts
- Lipocine presented Phase 3 clinical data for LPCN 1154 (oral brexanolone) for postpartum depression at ASCP Annual Meeting on May 26, 2026
- Presentation and poster are furnished as Exhibit 99.1 and 99.2
Financial Impact
No financial figures reported
Risk Factors
- Phase 3 data may not meet efficacy endpoints
- Competitive landscape includes other PPD treatments like Zulresso (brexanolone) and zuranolone
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025270 |
| Document: 0001493152-26-025270-index-headers.html | 0001493152-26-025270 |
| Document: 0001493152-26-025270-index.html | 0001493152-26-025270 |
| Document: 0001493152-26-025270.txt | 0001493152-26-025270 |
17 reports for LPCN
67% Hit rate @ T+60 Went positive at some point 4 of 5 best @ T+60▲ +11.72%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.62 | awaiting T+60 | — | $1.45 (−10.49%) |
Oct 7, 2026 19d ago | 8-K | $2.20 | awaiting T+60 | — | $1.45 (−34.09%) |
Sep 16, 2026 5w ago | 8-K | $2.22 | awaiting T+60 | — | $1.45 (−34.68%) |
Sep 14, 2026 6w ago | 8-K | $2.22 | awaiting T+60 | — | $1.45 (−34.68%) |
Sep 11, 2026 6w ago | 8-K | $2.27 | awaiting T+60 | — | $1.45 (−36.12%) |
Sep 10, 2026 6w ago | 8-K | $2.25 | awaiting T+60 | — | $1.45 (−35.56%) |
Aug 4, 2026 11w ago | Press Release | $2.13 | awaiting T+60 | — | $1.45 (−31.92%) |
Aug 3, 2026 12w ago | 8-K | $2.11 | awaiting T+60 | — | $1.45 (−31.28%) |
Jun 4, 2026 20w ago | 8-K | $2.21 $2.17 | ▼ −1.81% | ▼ −3.69% | $1.45 (−34.39%) |
May 26, 2026 21w ago | 8-K | $2.28 $2.09 | ▼ −8.33% | ▼ −10.21% | $1.45 (−36.40%) |
Showing 10 of 17
US Market Status
Market Closed — Opens Tue (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers